UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles

PloS one, 2012-05, Vol.7 (5), p.e38129

2012

Volltextzugriff (PDF)

Triage through telemedicine in paediatric emergency care-Results of a concordance study

PloS one, 2022-05, Vol.17 (5), p.e0269058-e0269058

2022

Volltextzugriff (PDF)

PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO

Oncoimmunology, 2017-10, Vol.6 (10), p.e1343775-e1343775

2017

Volltextzugriff (PDF)

Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model

Frontiers in immunology, 2023-01, Vol.13, p.1023206-1023206

2023

Volltextzugriff (PDF)

Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models

Cancers, 2023-01, Vol.15 (3), p.904

2023

Volltextzugriff (PDF)

Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice

PloS one, 2018-11, Vol.13 (11), p.e0207320-e0207320

2018

Volltextzugriff (PDF)

Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody

PloS one, 2014-09, Vol.9 (9), p.e107692

2014

Volltextzugriff (PDF)

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta

Cancers, 2023-06, Vol.15 (13), p.3317

2023

Volltextzugriff (PDF)

Tumorimmuntherapie in der pädiatrischen Onkologie

Der Onkologe, 2021-05, Vol.27 (5), p.470-477

Lode, Holger N.

2021

Volltextzugriff (PDF)

Bioactivation of Self-Immolative Dendritic Prodrugs by Catalytic Antibody 38C2

Journal of the American Chemical Society, 2004-02, Vol.126 (6), p.1726-1731

2004

Volltextzugriff (PDF)

Integrative medicine during the intensive phase of chemotherapy in pediatric oncology in Germany: a randomized controlled trial with 5-year follow up

BMC cancer, 2022-06, Vol.22 (1), p.652-652, Article 652

2022

Volltextzugriff (PDF)

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD2 Antibody Dinutuximab Beta

Cancers, 2022-10, Vol.14 (19), p.4842

2022

Volltextzugriff (PDF)

Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials

Cancers, 2022-04, Vol.14 (8), p.1919

2022

Volltextzugriff (PDF)

Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy

Cancers, 2023-06, Vol.15 (13), p.3364

2023

Volltextzugriff (PDF)

Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment

Frontiers in immunology, 2021-07, Vol.12, p.690467-690467

2021

Volltextzugriff (PDF)

Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments

Cancers, 2022-11, Vol.14 (23), p.5802

2022

Volltextzugriff (PDF)

Implementation of a combined CDK inhibition and arginine-deprivation approach to target arginine-auxotrophic glioblastoma multiforme cells

Cell death & disease, 2022-06, Vol.13 (6), p.555-14, Article 555

2022

Volltextzugriff (PDF)

Pediatric Hematology and Oncology Center Integrated by Telemedicine: Experience, Challenges and First Results of a Cross Border Network

Healthcare (Basel), 2023-05, Vol.11 (10), p.1431

2023

Volltextzugriff (PDF)

Reduction of CD11b+ myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD2 antibody ch14.18/CHO

Oncoimmunology, 2020-01, Vol.9 (1), p.1836768-1836768

2020

Volltextzugriff (PDF)

Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2

Oncoimmunology, 2019-12, Vol.8 (12), p.1661194-1661194

2019

Volltextzugriff (PDF)

GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18

Frontiers in immunology, 2022-03, Vol.13, p.839783-839783

2022

Volltextzugriff (PDF)

Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse

Journal of clinical medicine, 2023-09, Vol.12 (19), p.6196

2023

Volltextzugriff (PDF)

1 – 25 von 195

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(182)
Mit Volltextzugriff
(188)

Publikationsform

Sprache

Englisch
(192)
Japanisch
(8)
Deutsch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles

Mutational dynamics between primary and relapse neuroblastomas

Triage through telemedicine in paediatric emergency care-Results of a concordance study

PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)

Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model

Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models

Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice

Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta

Tumorimmuntherapie in der pädiatrischen Onkologie

Bioactivation of Self-Immolative Dendritic Prodrugs by Catalytic Antibody 38C2

Integrative medicine during the intensive phase of chemotherapy in pediatric oncology in Germany: a randomized controlled trial with 5-year follow up

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD2 Antibody Dinutuximab Beta

Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials

Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy

Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment

Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments

Implementation of a combined CDK inhibition and arginine-deprivation approach to target arginine-auxotrophic glioblastoma multiforme cells

Pediatric Hematology and Oncology Center Integrated by Telemedicine: Experience, Challenges and First Results of a Cross Border Network

Reduction of CD11b+ myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD2 antibody ch14.18/CHO

Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2

GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18

Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Suchergebnisse filtern